Risultati e situazione finanziariaSalute - farmaceutica - biotech
Inside Information / Other news releases
09/11/2026 18:00
AMFPubblicazione immediata
6:00 pm CET - Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces that the lastest…
PRESS RELEASE
Lyon, November 9, 2026
ADOCIA to Present Preclinical Data from its
AdoXLong™ Platform at ObesityWeek® 2026
6:00 pm CET - Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces that the lastest preclinical data on its AdoXLong™ platform will be presented as a poster at the ObesityWeek® 2026, taking place in Washington, USA, from November 14 – 17, 2026.
Poster Details:
Title: AdoXLong: A Long-Acting Peptide Platform Enabling Once-Monthly Administration of Incretins Poster Presentation: Saturday, November 14, 2026, 7:30 - 8:30 pm EST (Washington, USA)
Session: Gut Peptides, Appetite Signaling & Novel Therapeutics
Presenter: Martin Gaudier, PhD
About AdoXLong™
Adocia has developed a new platform, AdoXLong™, to address a critical challenge in diabetes and obesity treatments based on GLP-1 agonists, amylin, or other metabolic peptides: extend the duration of action of products currently administered weekly to reach a monthly injection. Beyond patient comfort it aims to provide, a monthly dosage form is intended to reduce the high discontinuation rate for these treatments observed within the first year, thereby enabling patients to fully benefit from the long-term metabolic effects of these therapies, which are lost when treatment is discontinued.
AdoXLong™ technology, for which Adocia has filed a patent application in November 2025, is a long-acting peptide platform composed of a biocompatible polymer chemically linked to the peptides without modifying their mechanisms of action. The technology is designed to offer a long circulating peptide over at least one month. The technology can be applied to a variety of peptides such as GLP-1, GIP, amylin, or dual/triple agonists
- including semaglutide, tirzepatide, cagrilintide – with the possibility to combine these modified peptides with each other.
The patent application is expected to provide worldwide protection until 2046, if granted. The peptides using the technology would also benefit from reinforced intellectual property with an extension until 2046. The technology is applicable to both innovative and biosimilar peptides, including semaglutide, which will become off-patent starting in 2026 in certain territories.
Positive preliminary in vitro results have also been obtained with AdoXL Retatrutide, further validating the platform nature of AdoXLong™. Adocia intends to continue developing its AdoXLong™ platform to advance toward clinical development.